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INTRODUCTION 
The prognosis of breast cancer is usually determined by
the disease stage (TNM stage) after surgery that assesses the
size of tumor (T), the status of metastasis to adjacent lymph
nodes (N), and the presence or absence of distant metastasis
to other organs (M). The prognosis of patients classified
according to TNM stage is different even in the same stage.
In other words, in the same stage of breast cancer, the prog-
nosis depends on the expression of estrogen or progesterone
receptor (ER or PR) and the over-expression of HER2 pro-
tein or the amplification of the gene. Therefore, some inves-
tigators have proposed a new staging system for breast can-
cer including such prognostic factors mentioned above (1). 
So far, the over-expression of HER2 protein or the ampli-
fication of the gene has been recognized as a prognostic fac-
tor of breast cancer and to be associated with poor prognosis
(2-7). However, it has been also claimed that the prognostic
significance of HER2 is found not in all breast cancer, but
only in advanced cases with lymph node metastasis (8). Thus,
it is still a controversial issue. Recently, the therapeutic effect
of the targeted therapy using trastuzumab for breast cancer
has been approved in adjuvant setting (9, 10). So, the clini-
cal significance of HER2 is increased in the determination
of indication for targeted therapy as well as of prognosis of
breast cancer. 
Test methods to assess HER2 status are diverse from gene
level to protein level. Immunohistochemistry (IHC) for the
detection of HER2 proteins is relatively easy, simple, cheap,
and thus performed widely, but has a great shortcoming of
the variable interpretation of the same results, i.e., lack of
objectivity of results. Therefore, for a vague result obtained
by immunohistochemical staining method, it is recommend-
ed to assess the accurate status of HER2 gene amplification
by performing fluorescence in-situ hybridization (FISH)
because its accuracy and reliability are high, even though
expensive (11-13). Therefore, the results by FISH are more
significant than that of IHC in determination of effects of
HER2 on the prognosis of breast cancer.
In this study, we performed FISH for the detection of HER2
gene amplification and investigated the prognostic signifi-
cance of HER2 according to the stages of breast cancer.
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Prognostic Significance of HER2 Gene Amplification According to
Stage of Breast Cancer
It is well known that the amplification of the HER2 gene is closely associated with
poor prognosis of breast cancer. However, there is controversy about the clinical
significance of HER2 according to lymph node status in breast cancer. The aim of
this study was to identify the differences in the prognostic significance of HER2 gene
amplification according to the stages of breast cancer. We prepared a tissue array
for fluorescence in situ hybridization (FISH) with breast cancer specimens from the
surgery in 1994 to 1999. Total 338 cases of breast cancer were enrolled and the
median follow-up period was 6.3 yr. The detection rates of HER2 gene amplifica-
tion were as follows: 10.3% in stage I, 22.3% in stage II, and 43.8% in stage III. On
survival analyses HER2-positive groups showed worse prognosis in stage III of
breast cancer, but not in stage I or II. Multivariate analyses with a Cox-regression
model also revealed that HER2 amplification was an independent prognostic fac-
tor only in stage III breast cancer. Regarding HER2 gene amplification as a prog-
nostic factor of breast cancer, the clinical significance of the gene was found to be
confined to advanced breast cancer. 
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MATERIALS AND METHODS
Subjects
Among the cases of patients underwent mastectomy for
breast cancer with invasive ductal carcinoma (NOS) at our
institution from January 1994 to December 1999, 338 cases
were enrolled in this study who were available for the retro-
spective examination of medical records and the follow-ups
as well as feasible for the amplification of HER2 gene test
with good condition of the stored paraffin-embedded tissues.
The subjects had never been treated with trastuzumab before
this study and had a sufficient follow-up period.
Methods
Preparation of tissue array
The area representing the histological finding of breast can-
cer in the paraffin-embedded tissues of each case was assessed
by microscope, and from the area, tissues were obtained using
a punch 3 mm in diameter, and 30 cases of tissues per array
block were aligned. 
Test for amplification of HER2 gene by fluorescence in situ
hybridization 
The paraffin-embedded tissue array blocks were sectioned
at 4 μ m thickness, attached to slides, and after performing
the deparaffinization and hydration process, using a commer-
cialized HER2 FISH kit (Vysis Inc, Downers Grove, Ill),
experiments were performed according to the guideline of
the manufacturer. First, the samples were treated with dilut-
ed wash buffer for 2 min, treated with pre-treatment solu-
tion at 95-99℃ for 10 min, and washed with wash buffer
for 3 min twice. The samples were treated with pepsin reagent
for 10 min, washed with wash buffer for 3 min twice, and
dehydrated. Subsequently, the samples were treated with
HER2/CEN-17 Probe Mix at 82℃ for 5 min, incubated in
a 45℃humidified hybridization chamber for 14-20 hr, and
treated with stringent wash buffer at 65℃for 10 min. Wash-
ed again with wash buffer for 3 min twice, the samples were
dehydrated, and a fluorescent mounting solution containing
4′ -6-diamidine-2-phenylindole (DAPI) was applied to slides
and read. In normal cells, CEN-17 DNA probe bound to
the centromere area of chromosome 17 and thus 1-2 green
fluorescent signal was shown, and HER2 DNA probe bound
to the HER2 gene and thus 1-2 red fluorescent signal was
shown, and the cases whose HER2/CEN-17 ratio was high-
er than 2 were considered to be positive for the amplifica-
tion of HER2 gene.
Survival survey and survival analysis 
Through the examination of the medical records of the sub-
ject patients and the records of the visit to our outpatient clin-
ic, the survival status of patients was assessed, and for patients
who did not have the record of the visit to hospital for longer
than 6 months, the survival survey was performed by tele-
phone. The analysis of the survival of patients was performed
by obtaining the Kaplan-Meier survival curve. Comparing
and analyzing survival data by Log-rank test. The determi-
nation of independent prognostic factors on the survival was
performed by multivariate analysis by applying Cox regres-
sion model. A p value less than 0.05 was considered to be
statistically significant. 
RESULTS
Characteristics of the subjects
The median age of the entire subjects was 48 yr, and the
median duration of follow-ups was 6.3 yr (Table 1). With
regard to the distribution of the stages of breast cancer, the
stage I was 58 cases (17.2%), the stage II was 184 cases (54.4
%), and the stage III was 96 cases (28.4%), and concerning
surgical treatment, mastectomy was performed on 301 cases
(89.0%), and postoperative adjuvant chemotherapy and hor-
mone therapy were performed by considering the status of
lymph node metastasis and hormone receptor test. In the
status of hormone receptors of breast cancer, of 288 tested
cases, 190 cases (66.0%) were found to be positive, and in
the HER2 test by FISH of breast cancer, positive results
meaning the amplification of the HER2 gene was shown in
89 cases of the total 388 cases (26.3%).
Variables Result
Age (yr) Median (range) 48 (23-78)
Follow-up period (yr) Median 6.3 (0.2-14.6)
Stage I 58 (17.2%)
II 184 (54.4%)
IIA 126 (37.3%)
IIB 57 (16.9%)
III 96 (28.4%)
IIIA 51 (15.1%)
IIIB 0 (0%)
IIIC 46 (13.6%)
Surgery MRM 301 (89.0%)
BCS 37 (11.0%)
ER/PR +/+ 129 (38.2%)
+/- 32 (9.5%)
-/+ 30 (8.9%)
-/- 98 (29.0%)
Unknown 49 (14.5%)
HER2 (FISH) + 89 (26.3%)
- 249 (73.7%)
Table 1. Clinicopathological characteristics of 338 cases of
breast cancer 
MRM, modified radical mastectomy; BCS, breast-conserving surgery;
ER, estrogen receptor; PR, progesterone receptor; FISH, fluorescence
in situ hybridization.416 Y.-S. Kim, Y.S. Won, K.S. Park, et al.
Results of HER2 test according to the stage 
In 89 cases showing the result of the amplification of
HER2 gene in breast cancer, the positivity was examined
according to the stage (Table 2). The positive result was
detected in 6 cases of the stage I (10.3%), 41 cases in the
stage II (22.3%), and 42 cases in the stage 3 (43.8%), hence,
it was found that the positive rate became higher as the dis-
ease stage progressed.
Survival analyses according to the stage
In the survival analysis based on the disease-free period,
the 5-yr survival rate according to the amplification of HER2
gene showed different results among the stages of breast can-
cer (Fig. 1). In the stage I breast cancer, the 5-yr disease-free
survival (DFS) rate of the HER2 gene positive group was
100%, the survival rate of the negative group was 85%, and
the survival rate of the positive group was higher, but it was
not statistically significant (p=0.2053). In the stage II breast
cancer, the 5-yr DFS rate of the positive group was 85%, that
of the negative group was 87%, and a difference was not sig-
nificant (p=0.3855). However, in the stage III breast cancer,
the DFS rate of positive group was 41%, that of the nega-
tive group was 70.5%, and the DFS rate of the HER2 gene-
positive group was significantly lower (p=0.0090).
In the survival analysis based on the overall survival peri-
od, similarly, the 5-yr survival rate according to the amplifi-
cation of HER2 gene showed different results depending on
the stages of breast cancer (Fig. 2). In the stage I breast can-
cer, the 5-yr overall survival (OS) rate of the HER2-positive FISH, fluorescence in situ hybridization.
Stage
HER2 (FISH)
+ -
Stage I (n=58) 6 (10.3%) 52 (89.7%)
Stage II (n=184) 41 (22.3%) 143 (77.7%)
StageIII (n=96) 42 (43.8%) 54 (56.3%)
Table 2. HER2 gene amplification according to the stages of
breast cancer
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Fig. 1. Disease-free survival (DFS) curves according to the stages
of breast cancer. (A) stage I (B) stage II (C) stage III. Statistical
significance between HER2 gene amplification -positive group
(solid line) and -negative group (dotted line) was noted only in
stage III of breast cancer. 
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group was 100% and that of the negative group was 94%.
In the stage II breast cancer, the OS rate of the positive group
was 88% and that of the negative group was 92.5%, and
the difference was not significant (p=0.5927 in the stage I,
p=0.8566 stage II). However, in the stage III breast cancer,
the 5-yr OS rate of the HER2-positive group was 28% and
that of the negative group was 60%, and the difference was
significant (p=0.0034).
Prognostic factors influencing survival
To examine prognostic factors that independently influ-
ence the disease-free survival and the overall survival, multi-
variate analysis was performed by Cox regression model
(Table 3). As an important prognostic factor influencing
recurrence and death, the statistical significance of the posi-
tive finding of HER2 was confirmed. The risk of recurrence
of the HER2 gene amplification-positive group was 1.669
times higher than that of the negative group (p=0.036), and
the risk of death was 2.394 times higher (p=0.003). On the
other hand, in the same analysis performed according to the
disease stage, the amplification of HER2 gene did not show
any significant effect on recurrence and survival in the dis-
ease stage I and II breast cancer, but in the stage III breast
cancer, increased the risk of recurrence by 2.678 times (p=
0.002) and the risk of death by 2.576 times (p=0.005). There-
fore, the significance as a prognostic factor could be confirm-
ed only in the stage III breast cancer (Table 4). 
Stage I
Fig. 2. Overall survival (OS) curves according to the stages of
breast cancer. (A) stage I (B) stage II (C) stage III. Statistical sig-
nificance between HER2 gene amplification -positive group (solid
line) and -negative group (dotted line) was noted only in stage III
of breast cancer. 
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Variables
DFS
RR 95% C.I. p
OS
RR 95% C.I. p
Tumor size (cm) 1.156 1.029-1.299 0.015 1.150 0.998-1.324 0.053
Node (number) 1.053 1.036-1.069 0.000 1.056 1.036-1.078 0.000
ER 0.997 0.634-1.570 0.991 0.777 0.448-1.349 0.370
HER2 (FISH) 1.669 1.035-2.690 0.036 2.394 1.384-4.140 0.002
Table 3. Multivariate analyses for disease-free survival and over-
all survival in all cases (Cox regression model)
RR, relative risk; C.I., confident interval; DFS, disease-free survival; OS,
overall survival; ER, estrogen receptor; FISH, fluorescence in situ hyb-
ridization.418 Y.-S. Kim, Y.S. Won, K.S. Park, et al.
DISCUSSION
The significance of this study is that the amplification of
the HER2 gene, which has been reported to be closely asso-
ciated with the prognosis of breast cancer, was re-examined
and the effect on the prognosis of the same stage breast can-
cer was assessed by survival analysis based on the long-term
follow-ups over than 5 yr. As mentioned already in the intro-
duction, to raise the reliability of HER2 test, in our study,
HER2 results were assessed by gene amplification test using
FISH, which could be also considered to be greatly mean-
ingful for the understanding of the significance HER2 as a
prognostic factor. However, this study was performed retro-
spectively and the number of patients in stage I was rela-
tively small to that of other stages due to the retrospective
selection of appropriate tissues of breast cancer for HER2
FISH test and survival analyses. These would be a limita-
tion of this study.
Generally, the positive rate of HER2 in breast cancer has
been reported to be 20-30% (14-17), and in our study, sim-
ilarly, the positive rate of the amplification of HER2 was
found to be 26.3%, and thus it could be confirmed. Never-
theless, HER2-positive rate showed a difference depending
on the stage of breast cancer, and the positive result was shown
in 10.3% in the stage I, 22.3% in stage II, and 43.8% in the
stage III. This result suggests that as the disease stage of breast
cancer is advanced, HER2-positive rate increases, and HER2
positivity is closely associated with high stage of breast can-
cer, that is, poor prognosis (18-20).
According to the summary of HER2 of breast cancer report-
ed until 1998 by Revillion et al. (18), HER2-positive result
was a marker representing the aggressiveness of tumors and
showed poor prognosis, nonetheless, because of the associa-
tion with other strong prognostic factors, it did not have a
clinically important significance. Slamon et al. (16) and Tan-
don et al. (21) have reported that the amplification of the
HER2 gene in breast cancer assessed by Southern blot had
been associated with poor prognosis and these results had
been found only in the lymph node positive group, but not
in the lymph node negative group. These results are similar
to our results in this study. We stratified the patients not by
nodal status but by stages of breast cancer to exclude the
influence of other prognostic factors such as tumor size, hor-
monal status as well as nodal status. In this study the pure
prognostic effect of HER2 gene amplification was noted only
in stage III patients of breast cancer, not in stage I or II. We
could suggest an explanation for these results that the ad-
vance of breast cancer would be associated with the increas-
ed amplification of the HER2 gene and the longer duration
of HER2 gene action than in early breast cancer (22), there-
fore, stage III of breast cancers in this study might have
taken sufficient chances to express harmful effects on their
survival not only by HER2 signal transduction pathway but
also by crosstalks with other signal transduction pathways
such as ER pathway. 
On the other hand, Borg et al. (23) have reported that, with
the result obtained by the same method, the amplification
of HER2 gene did not influence prognosis in both lymph
node -positive and -negative group. Afterwards, in numerous
results applied immunohistochemical staining method, sim-
ilar results were shown (24, 25), and until now, a clear con-
clusion could not be reached and it is a controversial issue.
HER2 as a prognostic factor assessed by multivariate
analysis, the amplification of the HER2 gene was confirmed
to increase the risk of recurrence by 1.669 times (p=0.0036),
and the risk of death by 2.394 times (p=0.002) in overall
cases of breast cancer. However, our result showed that the
effect of the amplification of HER2 gene differs depending
on the disease stage. In other words, the prognosis of the
HER2 gene amplification group was poor only in the stage
III breast cancer, and in the stage I and II breast cancer, a
statistically significant difference from the negative group
was not detected. In multivariate analysis performed accord-
ing to the stage of breast cancer, as the disease stage is ad-
vanced, the amplification of the HER2 gene was associated
with a high risk level of death, however, the statistical sig-
Variables
DFS
RR 95% C.I. p
OS
RR 95% C.I. p
Stage I
Tumor size  0.286 0.059-1.387 0.120 1.466 0.003-805.141 0.905
(cm)
ER 1.001 0.992-1.010 0.814 0.690 0.312-1.528 0.361
HER2 (FISH) 0.000 0.000 0.991 0.000 0.000 0.996
Table 4. Multivariate analyses of disease-free survival and over-
all survival according to the stages of breast cancer
Variables
DFS
RR 95% C.I. p
OS
RR 95% C.I. p
Stage II
Tumor size 0.910 0.666-1.247 0.552 0.815 0.536-1.242 0.341
(cm)
Node (number) 1.236 1.090-1.402 0.001 1.307 1.133-1.508 0.000
ER 0.724 0.330-1.590 0.422 0.455 0.155-1.331 0.150
HER2 (FISH) 0.715 0.238-2.146 0.549 1.370 0.415-4.520 0.606
Variables
DFS
RR 95% C.I. p
OS
RR 95% C.I. p
Stage III
Tumor size  1.209 1.063-1.374 0.004 1.131 0.975-1.313 0.103
(cm)
Node (number) 1.027 1.004-1.050 0.020 1.015 0.986-1.045 0.312
ER 1.302 0.708-2.394 0.396 0.987 0.512-1.902 0.969
HER2 (FISH) 2.678 1.437-4.991 0.002 2.576 1.339-4.959 0.005
DFS, disease-free survival; OS, overall survival; RR, relative risk; C.I.,
confidence interval; ER, estrogen receptor; FISH, fluorescence in situ
hybridization.Breast Cancer Stages and HER2 Gene Amplification  419
nificance was noted only in the stage III breast cancer. There-
fore, based on the result of our study, it could be confirmed
that the amplification of the HER2 gene exerts a poor effect
only on the prognosis of advanced breast cancer.
In conclusion, the amplification of the HER2 gene in breast
cancer confirmed by FISH was associated with the progres-
sion of the disease stage of breast cancer, and the clinical sig-
nificance as a prognostic factor might be confined only in
advanced breast cancer. 
REFERENCES
1. Veronesi U, Viale G, Rotmensz N, Goldhirsch A. Rethinking TNM:
Breast cancer TNM classification for treatment decision-making
and research. Breast 2006; 15: 3-8.
2. Dykins R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C,
Lennard TJ, Angus B, Horne CH. Long-term survival in breast can-
cer related to overexpression of the c-erbB-2 oncoprotein: an immuno-
histochemical study using monoclonal antibody NCL-CB11. J Pathol
1991; 163: 105-10.
3. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlof-
sky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson
R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M,
Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready
D. neu/erbB-2 amplification identifies a poor-prognosis group of
women with node-negative breast cancer. Toronto Breast Cancer
Study Group. J Clin Oncol 1998; 16: 1340-9.
4. Hartmann LC, Ingle JN, Wold LE, Farr GH Jr, Grill JP, Su JQ, Maihle
NJ, Krook JE, Witzig TE, Roche PC. Prognostic value of c-erbB2
overexpression in axillary lymph node positive breast cancer. Results
from a randomized adjuvant treatment protocol. Cancer 1994; 74:
2956-63.
5. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz
M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Paterson MC,
Slammon DJ. Her-2/neu expression in node-negative breast cancer:
direct tissue quantitation by computerized image analysis and asso-
ciation of overexpression with increased risk of recurrent disease.
Cancer Res 1993; 53: 4960-70.
6. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen
P. Clinical significance of HER-2/neu oncogene amplification in
primary breast cancer. The South Australian Breast Cancer Study
Group. J Clin Oncol 1993; 11: 1936-42.
7. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncopro-
tein expression in node-positive breast cancer. The influence of the
pattern of immunostaining and adjuvant therapy. Cancer 1994; 73:
2359-65.
8. Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi
R, Ciatto S. Prognostic significance of c-erbB-2 expression in node
negative breast cancer. Br J Cancer 1993; 67: 625-9.
9. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, David-
son NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM,
Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher
DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas
EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastzumab plus
adjuvant chemotherapy for operable HER2-positive breast cancer.
N Engl J Med 2005; 353: 1673-84.
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A,
Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron
D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar
M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch
C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C,
McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA)
Trial Study Team. Trastzumab after adjuvant chemotherapy in HER2-
positive breast cancer. N Engl J Med 2005; 353: 1659-72.
11. Ellis CM, Dyson MJ, Stephenson TJ, Maltby EL. HER2 amplifica-
tion status in breast cancer: a comparison between immunohisto-
chemical staining and fuorescence in situ hybridization using man-
ual and automated quantitative image analysis scoring techniques.
J Clin Pathol 2005; 58: 710-14.
12. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y,
Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips
RN, Ross JS, Wolman SR, Flom KJ. HER-2/neu gene amplification
characterized by fluorescence in situ hybridization: poor prognosis
in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894-
904.
13. Ratcliffe N, Wells W, Wheeler K, Memoli V. The combination of in
situ hybridization and immunohistochemical analysis: an evaluation
of Her2/neu expression in paraffin-embedded breast carcinomas and
adjacent normal-appearing breast epithelium. Mod Pathol 1997;
10: 1247-52.
14. Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith
HS, Waldman FM, Pinkel D, Gray JW. ERBB2 amplification in
breast cancer analyzed by fluorescence in situ hybridization. Proc
Natl Acad Sci USA 1992; 89: 5321-5.
15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire
WL. Human breast cancer: correlation of relapse and survival with
amplification of the HER-2/neu oncogene. Science 1987; 235: 177-
82.
16. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE,
Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the
HER-2/neu proto-oncogene in human breast and ovarian cancer.
Science 1989; 244: 707-12.
17. Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin
S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, Wood WC.
Analysis of c-erbB-2 expression in breast carcinomas with clinical
follow-up. Cancer Res 1989; 49: 7147-52.
18. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human
breast cancer and its clinical significance. Eur J Cancer 1998; 34:
791-808.
19. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer:
prognostic factor, predictive factor, and target for therapy. Stem
Cells 1998; 16: 413-28.
20. Tagliabue E, Menard S, Robertson JF, and Harris L. c-erbB-2 expres-
sion in primary breast cancer. Int J Biol Markers 1999; 14: 16-26.
21. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL.
HER-2/neu oncogene protein and prognosis in breast cancer. J Clin
Oncol 1989; 7: 1120-8.
. .420 Y.-S. Kim, Y.S. Won, K.S. Park, et al.
22. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B.
Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and
p53 in invasive mammary ductal carcinoma associated with ductal
carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Anti-
cancer Res 2005; 25: 1719-23.  
23. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua
SA, Killander D, McGuire WL. HER-2/neu amplification predicts
poor survival in node-positive breast cancer. Cancer Res 1990; 50:
4332-7.
24. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgan P, Norton L.
Immunohistochemical detection of HER-2/neu in patients with axil-
lary lymph node negative breast carcinoma. A study of epidemio-
logic risk factors, histologic features, and prognosis. Cancer 1995;
75: 1320-6.
25. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J.
The prognostic value of p53 and C-erb-B2 immunostaining is over-
rated for patients with lymph node-negative breast carcinoma?: a
multivariate analysis of prognostic factors in 613 patients with a
follow up of 14-30 years. Cancer 2000; 88: 804-13.